7 March 2016 - Pharmac's assignment of a low-funding priority to pembrolizumab (Keytruda) for advanced melanoma has brought cancer drug funding back to the centre stage of national debate.

For more details, go to: http://www.stuff.co.nz/science/77538107/real-urgent-plight-for-melanoma-patients-hoping-for-better-keytruda-funding